Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP10 | P09238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239384 | 1.00 | HSD11B1 (0.43) | HSD11B1MAOBTNFRSF1ATRPA1NFE2L2 | |
| SCHEMBL5236707 | 0.82 | OPRM1 (0.42) | MAOBTNFRSF1AALDH1A1LMNA | |
| SCHEMBL5236717 | 0.82 | OPRM1 (0.42) | MAOBTNFRSF1AALDH1A1LMNA | |
| SCHEMBL2238891 | 0.79 | JUN (0.43) | ALDH1A1ALOX5 | |
| SCHEMBL2238896 | 0.79 | JUN (0.43) | ALDH1A1ALOX5 | |
| SCHEMBL14782981 | 0.75 | PTP4A3 (0.43) | ALDH1A1 | |
| SCHEMBL14782980 | 0.75 | PTP4A3 (0.43) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL2238735 | 0.72 | JUN (0.41) | MAOBALDH1A1MAPK1 | |
| Trifluoroacetic Acid SCHEMBL2238726 | 0.72 | JUN (0.41) | MAOBALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL31556486 | 0.72 | CYP1A2 (0.44) | MAOBPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1761539-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | Takeda Pharmaceutical Company Limited (JP) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005118587-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | IGF1R, KDR, ERBB2 | HSD11B1 986/4885MAOB 106/4885TNFRSF1A 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.